Evidence map›Paper›PMID 40290845›Full record

ReviewEClinicalMedicine2025

Aligning kidney function assessment in patients with cancer to global practices in internal medicine.

Geeta Sandhu, Josephine Adattini, Evangeline Armstrong Gordon, Niamh O'Neill, Corrine Bagnis, Pinkie Chambers, Jennifer H Martin, Alex Flynn, Karim Ibrahim, Meg J Jardine and 25 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Geeta SandhuFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Josephine AdattinieviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Evangeline Armstrong GordoneviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Niamh O'NeilleviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Corrine BagnisNephrology Department, APHP Sorbonne University, Paris, France.
Pinkie ChambersUniversity College London School of Pharmacy and University College London Hospital-University College London Centre for Medicines Optimisation Research and Education, London, United Kingdom.
Jennifer H MartinCentre for Drug Repurposing, University of Newcastle, Newcastle, NSW, Australia.
Alex FlynnCentre for Drug Repurposing, University of Newcastle, Newcastle, NSW, Australia.
Karim IbrahimFaculty of Medicine and Health, The University of New South Wales, Sydney, NSW, Australia.
Meg J JardineNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
David W JohnsonAustralasian Kidney Trials Network, The University of Queensland, Brisbane, QLD, Australia.
Graham R D JonesFaculty of Medicine and Health, The University of New South Wales, Sydney, NSW, Australia.
Christos S KarapetisFlinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, Australia.
Aisling KellyeviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Ganessan KichenadasseFlinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, Australia.
David S KlimanDepartment of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia.
Winston LiauwCancer Care Centre, St George Hospital, Kogarah, NSW, Australia.
Catherine LucasCentre for Drug Repurposing, University of Newcastle, Newcastle, NSW, Australia.
Andrew J MallettDepartment of Renal Medicine, Townsville University Hospital, Townsville, QLD, Australia.
Jolanta MalyszkoDepartment of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Michael MichaelPeter MacCallum Cancer Centre, Parkville, VIC, Australia.
Carol A PollockFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Darren M RobertsEdith Collins Centre, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Mitchell H RosnerDepartment of Medicine, University of Virginia Health, Charlottesville, VA, USA.
David J M RoutledgePeter MacCallum Cancer Centre, Parkville, VIC, Australia.
Carla ScuderiPharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Julia ShingletoneviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
Jake ShorttMonash Haematology, Monash Health, Clayton, VIC, Australia.
Jim SiderovPharmacy Department, Austin Health, Melbourne, VIC, Australia.
Ben SprangersBiomedical Research Institute, Department of Immunology and Infection, UHasselt, Diepenbeek, Belgium.
Brian N SteinICON Cancer Centre, Adelaide, SA, Australia.
David J TunnicliffeSydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.
Kate WebberDepartment of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Robyn L WardFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
ADDIKD Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The kidney disease: Improving Global Outcomes (KDIGO) guideline recommends assessing kidney function using glomerular filtration rate (GFR) either through direct measurement or through estimation (eGFR) and describes a standardised classification of reduced kidney function. KDIGO guidelines have been adopted by most internal medicine specialities for the assessment and classification of kidney function, but not by cancer medicine. The development of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) aims to overcome the perceived challenges with KDIGO recommendations by describing their utility in patients with cancer. Two virtual, consensus building workshops were held consecutively, involving international, multidisciplinary participants (Part 1 of ADDIKD development). During these workshops, three consensus recommendations were agreed upon based on KDIGO's principles; to standardise kidney function assessment, classify kidney function, and determine a uniform approach to dose anticancer drugs in patients with reduced kidney function. Cancer clinicians attending the workshops identified issues regarding the adoption of KDIGO's recommendations. These issues were addressed by nephrologists, clinical pharmacologists, and other clinicians with extensive experience in the contemporary assessment of kidney function. The key concern for cancer specialists was a hesitancy to move away from the familiar and long-standing practice of using the Cockcroft-Gault equation to estimate creatinine clearance. The consensus building within the two multidisciplinary workshops allowed a thorough assessment of the evidence and clarified how directly measured GFR and eGFR, rather than creatinine clearance, could be optimally utilised in cancer care. The development of Part 1 of the ADDIKD guideline represents a standardised, contemporary approach to the assessment, classification, and utility of kidney function in the setting of cancer care and it harmonises with the approach used in other areas of medicine internationally. Funding: Development of the ADDIKD guideline is funded by the Cancer Institute NSW as part of the NSW Government and received no funding from external commercial sources.

Indexed as

ChemotherapyDrug dosingHaematologyKidney dysfunctionOncologyPharmacokineticsRenal

Identifiers

PMID40290845
PMCPMC12034077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.